Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 4 25 M IN DEXTROSE 10 IN PLASTIC CONTAINER versus AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 4 25 M IN DEXTROSE 10 IN PLASTIC CONTAINER versus AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER.
AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER vs AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 4.25% M in Dextrose 10% is a combination of amino acids and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis, while dextrose provides a source of calories. The amino acids undergo transamination, deamination, and incorporation into body proteins. Dextrose is metabolized via glycolysis, the Krebs cycle, and oxidative phosphorylation to produce ATP.
Aminosyn II 4.25% w/ Electrolytes in Dextrose 25% is a parenteral nutrition formulation providing amino acids for protein synthesis and dextrose as a carbohydrate calorie source. The amino acids serve as substrates for protein synthesis, while dextrose provides glucose for cellular energy metabolism via glycolysis and the citric acid cycle. Electrolytes are included to maintain acid-base and fluid balance, and to support enzymatic functions and membrane potentials.
Intravenous infusion via central line. Adult dose: 500-2000 mL/day (equivalent to 21.25-85 g amino acids and 50-200 g dextrose) based on caloric and nitrogen requirements. Rate not to exceed 100 mL/hour initially, adjusted to maintain blood glucose <200 mg/dL.
Intravenous infusion. Adult dose: 500 mL to 1000 mL per 24 hours, adjusted to meet protein and calorie requirements. Typical infusion rate: 1.5-2.0 mL/kg/hour, not exceeding 3.0 mL/kg/hour.
None Documented
None Documented
Amino acids: variable; individual amino acid half-lives range from minutes to hours; dextrose: 1-2 hours; clinical context: continuous infusion required to maintain stable plasma levels.
Not applicable as a single entity; amino acids have rapid turnover (minutes to hours) with no terminal half-life. Dextrose has a half-life of 15-20 minutes under steady-state conditions.
Renal: amino acids are metabolized and nitrogen is excreted primarily as urea (80-90%) and ammonia (minor); dextrose is fully metabolized to CO2 and water; negligible biliary/fecal elimination.
Amino acids are metabolized to urea (liver) and CO2; nitrogen is excreted renally as urea (80-90%), with minimal (<5%) biliary/fecal. Dextrose is metabolized to CO2 (exhaled) and water. Electrolytes are excreted renally proportional to intake and homeostasis.
Category C
Category C
Amino Acid Solution
Amino Acid Solution